908 Devices Inc. develops and sells measurement devices for chemical and biochemical analysis in North America, Europe, the Middle East, Africa, and the Asia Pacific. It offers handheld and desktop mass spectrometry (Mass Spec) devices for the point-of-need applications in life sciences research, bioprocessing, industrial biotech, forensics, and adjacent markets. Its products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of gas, liquid, and solid materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and ZipChip, a plug-and-play, high-resolution separation platform that optimizes Mass Spec sample analysis. 908 Devices Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
IPO Year: 2020
Exchange: NASDAQ
Website: 908devices.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/13/2024 | $12.00 → $4.00 | Outperform → Market Perform | Leerink Partners |
| 2/7/2023 | $14.00 | Overweight | Stephens |
| 3/8/2022 | $40.00 → $30.00 | Outperform | SVB Leerink |
| 10/15/2021 | Outperform | Cowen |
Gainers Genasys (NASDAQ:GNSS) stock rose 10.0% to $2.2 during Tuesday's after-market session. The company's market cap stands at $96.8 million. As per the news, the Q2 earnings report came out today. AEye (NASDAQ:LIDR) shares rose 9.75% to $2.7. The company's market cap stands at $17.5 million. As per the news, the Q1 earnings report came out today. Sonim Technologies (NASDAQ:SONM) stock increased by 7.75% to $0.62. The company's market cap stands at $29.1 million. Mobix Labs (NASDAQ:MOBX) stock rose 4.99% to $3.36. The market value of their outstanding shares is at $90.2 million. The company's, Q2 earnings came out today. 908 Devices (NASDAQ:MASS) stock increased by 4.89% to $7.5. The
Stephens & Co. analyst Jacob Johnson reiterates 908 Devices (NASDAQ:MASS) with a Overweight and maintains $14 price target.
Although U.S. stocks closed mixed on Tuesday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company’s prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision. Below is a look at a few recent notable insider purchases. For more, check out Benzinga’s insider transactions platform. Aon The Trade: Aon plc (NYSE:AON) Director Lester B Knight acquired a total of 10,000 shares an average price of $276.61. To
Gainers Marin Software (NASDAQ:MRIN) stock increased by 35.2% to $3.53 during Tuesday's pre-market session. The market value of their outstanding shares is at $10.6 million. Auddia (NASDAQ:AUUD) shares rose 23.93% to $2.04. The market value of their outstanding shares is at $4.8 million. Blend Labs (NYSE:BLND) shares increased by 23.11% to $2.77. The company's market cap stands at $698.1 million. Movano (NASDAQ:MOVE) shares increased by 10.8% to $0.51. The company's market cap stands at $50.0 million. 908 Devices (NASDAQ:MASS) shares increased by 9.81% to $6.32. The company's market cap stands at $207.9 million. As per the news, the Q1 earnings report came out today. Aeva Technologies
908 Devices (NASDAQ:MASS) reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate of $(0.36) by 8.33 percent. This is a 15.38 percent increase over losses of $(0.39) per share from the same period last year. The company reported quarterly sales of $9.99 million which beat the analyst consensus estimate of $9.29 million by 7.55 percent. This is a 5.31 percent increase over sales of $9.49 million the same period last year.
On Thursday, Cathie Wood-led Ark Invest made some significant trades, with Coinbase Global Inc (NASDAQ:COIN) and Palantir Technologies Inc (NYSE:PLTR) being the most prominent. The Coinbase Trade Ark Invest sold a substantial number of Coinbase shares across three of its funds: ARK Innovation ETF (NYSE:ARKK), ARK Next Generation Internet ETF (NYSE:ARKW), and Ark Fintech Innovation ETF (NYSE:ARKF). The total number of shares sold was 54,215. The transaction was valued at $13.15 million. This move came as Bitcoin (CRYPTO: BTC) was nearing a new all-time high, flirting with the $69,000 mark. Coinbase shares closed at $242.62, up 1.71% for the day. The Palantir Trade On the other
908 Devices (NASDAQ:MASS) reported quarterly losses of $(0.23) per share which beat the analyst consensus estimate of $(0.26) by 11.54 percent. This is a 25.81 percent increase over losses of $(0.31) per share from the same period last year. The company reported quarterly sales of $14.35 million which beat the analyst consensus estimate of $14.16 million by 1.35 percent. This is a 23.26 percent increase over sales of $11.64 million the same period last year.
Revenue increases 17% compared to prior year, driven by recently acquired handheld products 908 Devices Inc. (NASDAQ:MASS), a pioneer of purpose-built handheld and desktop devices for chemical analysis, today reported financial results for the quarter ended September 30, 2024. "While we are pleased that our revenue increased year-over-year due to our newly acquired products, our third quarter results fell short of our expectations due to challenges from the delayed FY24 federal budget, delays with advancing international contracts, and ongoing softness in the bioprocessing and life science instrumentation market," said Kevin J. Knopp, CEO and Co-founder. "Despite near-term headwinds, we
908 Devices Inc. (NASDAQ:MASS), a pioneer of purpose-built handheld and desktop devices for chemical analysis, today announced it will participate in the following investor conferences. Stifel Healthcare Conference, New York, NY Fireside chat on Tuesday, November 19 at 8:35 a.m. Eastern Time 26th Annual Stephens Investment Conference, Nashville, TN Fireside chat on Wednesday, November 20 at 3 p.m. Central Time / 4 p.m. Eastern Time Interested parties may access a live and archived webcast of these sessions on the "Investors" section of the company website at: www.908devices.com. About 908 Devices 908 Devices is revolutionizing chemical analysis with its simple handheld and desktop
908 Devices Inc. (NASDAQ:MASS), a pioneer of handheld and desktop devices for chemical analysis, today announced it will report financial results for the third quarter 2024 before market open on Tuesday, November 12, 2024. Company management will webcast a corresponding conference call beginning at 8:30 a.m. Eastern Time / 5:30 a.m. Pacific Time. Live audio of the webcast will be available on the "Investors" section of the company website at: www.908devices.com. The webcast will be archived and available for replay within 24 hours after the event. About 908 Devices 908 Devices is revolutionizing chemical analysis with its simple handheld and desktop devices, addressing life-altering appli
908 Devices Inc. (NASDAQ:MASS), a pioneer of purpose-built handheld and desktop devices for chemical analysis, today announced it will participate in the upcoming virtual Craig-Hallum Bioprocessing Conference. 908 Devices' management is scheduled to host a fireside chat on Thursday, September 19 at 10:15 a.m. Eastern Time. Interested parties may access a replay webcast link following the conference on the "Investors" section of the company website at 908devices.com. About 908 Devices 908 Devices is revolutionizing chemical analysis with its simple handheld and desktop devices, addressing life-altering applications. The Company's devices are used at the point-of-need to interrogate unkno
Revenue increases 16% compared to prior year, driven by newly acquired handheld products 908 Devices Inc. (NASDAQ:MASS), a pioneer of purpose-built handheld and desktop devices for chemical analysis, today reported financial results for the quarter ended June 30, 2024. "We delivered solid execution on a multitude of fronts in the quarter, including the acquisition and integration of RedWave Technology into our company. With an expanded handheld portfolio, we are now supporting both our new and existing forensics customers more efficiently," said Kevin J. Knopp, CEO and Co-founder. "We also maintained a strong focus on operational excellence during the quarter and have begun to see early
908 Devices Inc. (NASDAQ:MASS), a pioneer of purpose-built handheld and desktop devices for chemical analysis, today announced it will participate in the upcoming Canaccord Genuity 44th Annual Growth Conference. 908 Devices' management is scheduled to present on Tuesday, August 13 at 1:00 p.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the "Investors" section of the company website at: 908devices.com. About 908 Devices 908 Devices is revolutionizing chemical analysis with its simple handheld and desktop devices, addressing life-altering applications. The Company's devices are used at the point-of-need to interrogate unknown and invisib
908 Devices Inc. (NASDAQ:MASS), a pioneer of handheld and desktop devices for chemical analysis, today announced it will report financial results for the second quarter 2024 before market open on Tuesday, August 6, 2024. Company management will webcast a corresponding conference call beginning at 8:30 a.m. Eastern Time / 5:30 a.m. Pacific Time. Live audio of the webcast will be available on the "Investors" section of the company website at: www.908devices.com. The webcast will be archived and available for replay within 24 hours after the event. About 908 Devices 908 Devices is revolutionizing chemical analysis with its simple handheld and desktop devices, addressing life-altering appli
908 Devices Inc. (NASDAQ:MASS), a pioneer of purpose-built handheld and desktop devices for chemical analysis, has appointed Michele M. Leonhart, the former Administrator of the United States Drug Enforcement Administration (DEA), to serve on its Board of Directors effective immediately. Ms. Leonhart brings a deep understanding of our customers in law enforcement and adjacent markets. Her 34-year career in the DEA encompassed various positions with increasing levels of responsibility, including Special Agent in Charge of the Los Angeles Field Division from 1998 to 2003, Deputy Administrator (nominated by President Bush) from 2003 to 2007, Acting Administrator from 2007 to 2010, and Admini
Updated technology enables first responders to identify and quantify approximately 5,000 substances in mere seconds for a swift and definitive response 908 Devices Inc. (NASDAQ:MASS), a pioneer of purpose-built handheld and desktop devices for chemical analysis, today announced an enhanced quantification package for its XplorIR handheld gas and vapor analyzer. With this software update, the device, part of 908 Devices' acquisition of RedWave Technology, can now quantify nearly 5,000 airborne chemicals. XplorIR empowers fire departments, HAZMAT teams and other first responders with mission-critical information and enables decisions around personal protective equipment, ensures swift remedi
908 Devices Inc. (NASDAQ:MASS), a pioneer of purpose-built handheld and desktop devices for chemical and biochemical analysis, today announced it will participate in the following investor conferences. 2024 Leerink Partners Healthcare Crossroads Conference, Austin, Texas Fireside chat on Wednesday, May 29 at 8:00 a.m. Central Time / 9:00 a.m. Eastern Time William Blair 44th Annual Growth Stock Conference, Chicago, Illinois Presentation on Tuesday, June 4 at 10:40 a.m. Central Time / 11:40 a.m. Eastern Time Interested parties may access a live and archived webcast of these sessions on the "Investors" section of the company website at: www.908devices.com. About 908 Devices 908 D
10-Q - 908 Devices Inc. (0001555279) (Filer)
8-K - 908 Devices Inc. (0001555279) (Filer)
10-Q - 908 Devices Inc. (0001555279) (Filer)
8-K - 908 Devices Inc. (0001555279) (Filer)
8-K/A - 908 Devices Inc. (0001555279) (Filer)
8-K - 908 Devices Inc. (0001555279) (Filer)
8-K - 908 Devices Inc. (0001555279) (Filer)
SD - 908 Devices Inc. (0001555279) (Filer)
10-Q - 908 Devices Inc. (0001555279) (Filer)
8-K - 908 Devices Inc. (0001555279) (Filer)
Leerink Partners downgraded 908 Devices from Outperform to Market Perform and set a new price target of $4.00 from $12.00 previously
Stephens initiated coverage of 908 Devices with a rating of Overweight and set a new price target of $14.00
SVB Leerink reiterated coverage of 908 Devices with a rating of Outperform and set a new price target of $30.00 from $40.00 previously
Cowen resumed coverage of 908 Devices with a rating of Outperform
SVB Leerink reiterated coverage of 908 Devices with a rating of Outperform and set a new price target of $65.00 from $70.00 previously
4 - 908 Devices Inc. (0001555279) (Issuer)
4 - 908 Devices Inc. (0001555279) (Issuer)
3 - 908 Devices Inc. (0001555279) (Issuer)
3 - 908 Devices Inc. (0001555279) (Issuer)
4 - 908 Devices Inc. (0001555279) (Issuer)
4 - 908 Devices Inc. (0001555279) (Issuer)
4 - 908 Devices Inc. (0001555279) (Issuer)
4 - 908 Devices Inc. (0001555279) (Issuer)
4 - 908 Devices Inc. (0001555279) (Issuer)
4 - 908 Devices Inc. (0001555279) (Issuer)
SC 13G/A - 908 Devices Inc. (0001555279) (Subject)
SC 13G/A - 908 Devices Inc. (0001555279) (Subject)
SC 13G/A - 908 Devices Inc. (0001555279) (Subject)
SC 13G/A - 908 Devices Inc. (0001555279) (Subject)
SC 13G - 908 Devices Inc. (0001555279) (Subject)
SC 13G - 908 Devices Inc. (0001555279) (Subject)
SC 13G - 908 Devices Inc. (0001555279) (Subject)
SC 13G/A - 908 Devices Inc. (0001555279) (Subject)
SC 13G/A - 908 Devices Inc. (0001555279) (Subject)
SC 13G/A - 908 Devices Inc. (0001555279) (Subject)
4 - 908 Devices Inc. (0001555279) (Issuer)
4 - 908 Devices Inc. (0001555279) (Issuer)
4 - 908 Devices Inc. (0001555279) (Issuer)
4 - 908 Devices Inc. (0001555279) (Issuer)
4 - 908 Devices Inc. (0001555279) (Issuer)
Revenue increases 17% compared to prior year, driven by recently acquired handheld products 908 Devices Inc. (NASDAQ:MASS), a pioneer of purpose-built handheld and desktop devices for chemical analysis, today reported financial results for the quarter ended September 30, 2024. "While we are pleased that our revenue increased year-over-year due to our newly acquired products, our third quarter results fell short of our expectations due to challenges from the delayed FY24 federal budget, delays with advancing international contracts, and ongoing softness in the bioprocessing and life science instrumentation market," said Kevin J. Knopp, CEO and Co-founder. "Despite near-term headwinds, we
908 Devices Inc. (NASDAQ:MASS), a pioneer of handheld and desktop devices for chemical analysis, today announced it will report financial results for the third quarter 2024 before market open on Tuesday, November 12, 2024. Company management will webcast a corresponding conference call beginning at 8:30 a.m. Eastern Time / 5:30 a.m. Pacific Time. Live audio of the webcast will be available on the "Investors" section of the company website at: www.908devices.com. The webcast will be archived and available for replay within 24 hours after the event. About 908 Devices 908 Devices is revolutionizing chemical analysis with its simple handheld and desktop devices, addressing life-altering appli
Revenue increases 16% compared to prior year, driven by newly acquired handheld products 908 Devices Inc. (NASDAQ:MASS), a pioneer of purpose-built handheld and desktop devices for chemical analysis, today reported financial results for the quarter ended June 30, 2024. "We delivered solid execution on a multitude of fronts in the quarter, including the acquisition and integration of RedWave Technology into our company. With an expanded handheld portfolio, we are now supporting both our new and existing forensics customers more efficiently," said Kevin J. Knopp, CEO and Co-founder. "We also maintained a strong focus on operational excellence during the quarter and have begun to see early
908 Devices Inc. (NASDAQ:MASS), a pioneer of handheld and desktop devices for chemical analysis, today announced it will report financial results for the second quarter 2024 before market open on Tuesday, August 6, 2024. Company management will webcast a corresponding conference call beginning at 8:30 a.m. Eastern Time / 5:30 a.m. Pacific Time. Live audio of the webcast will be available on the "Investors" section of the company website at: www.908devices.com. The webcast will be archived and available for replay within 24 hours after the event. About 908 Devices 908 Devices is revolutionizing chemical analysis with its simple handheld and desktop devices, addressing life-altering appli
First quarter 2024 product and service revenue increased 8% compared to prior year, driven by a 20% increase in handheld revenue Acquired RedWave Technology, expanding forensics product portfolio for point-of-need applications 908 Devices Inc. (NASDAQ:MASS), a pioneer of purpose-built handheld and desktop devices for chemical and biochemical analysis, today reported financial results for the quarter ended March 31, 2024. "We had a solid start to the year with topline revenue of $10 million for the first quarter and continued to see robust demand for our handheld devices as applications for chemical detection and identification at the point of need gain further traction in the US and i
Adds optical spectroscopy to the company's technology platform for point-of-need applications 908 Devices Inc. (NASDAQ:MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biochemical analysis, announces that it has completed the acquisition of privately-held RedWave Technology, a leading provider of portable FTIR spectroscopic analyzers for rapid chemical identification of bulk materials. FTIR (Fourier Transform Infrared), an optical spectroscopy technology, is highly regarded for its specific substance identification abilities across a broad range of bulk materials. This acquisition provides 908 Devices with an expanded portfolio of handheld chemic
908 Devices Inc. (NASDAQ:MASS), a pioneer of handheld and desktop devices for chemical and biochemical analysis, today announced it will report financial results for the first quarter 2024 before market open on Tuesday, April 30, 2024. Company management will webcast a corresponding conference call beginning at 8:30 a.m. Eastern Time / 5:30 a.m. Pacific Time. Live audio of the webcast will be available on the "Investors" section of the company website at: www.908devices.com. The webcast will be archived and available for replay within 24 hours after the event. About 908 Devices 908 Devices is revolutionizing chemical and biochemical analysis with its simple handheld and desktop devices,
Fourth quarter 2023 revenue increased 23% compared to prior year, driven by handheld revenue increasing 57% 908 Devices Inc. (NASDAQ:MASS), a pioneer of purpose-built handheld and desktop devices for chemical and biochemical analysis, today reported financial results for the quarter and full year ended December 31, 2023. "We made solid progress in 2023 towards our objectives. We have continued to see sustained growth of our handheld devices servicing customers in their efforts to combat the ongoing crisis of counterfeit drugs and opioids. For the full year we saw 28% growth in our handheld revenue and consistent year-over-year growth each quarter. Despite near-term headwinds impacting t
908 Devices Inc. (NASDAQ:MASS), a pioneer of handheld and desktop devices for chemical and biochemical analysis, today announced it will report financial results for the fourth quarter and full year 2023 before market open on Tuesday, March 5, 2024. Company management will webcast a corresponding conference call beginning at 8:30 a.m. Eastern Time / 5:30 a.m. Pacific Time. Live audio of the webcast will be available on the "Investors" section of the company website at: www.908devices.com. The webcast will be archived and available for replay within 24 hours after the event. About 908 Devices 908 Devices is revolutionizing chemical and biochemical analysis with its simple handheld and
908 Devices Inc. (NASDAQ:MASS), a pioneer of purpose-built handheld and desktop devices for chemical and biochemical analysis, today reported financial results for the quarter ended September 30, 2023. "We are pleased with the step-up in our revenues from the second quarter and the positive growth trend over the past nine months, despite the challenging environment in the life sciences instrumentation and bioprocessing markets," said Kevin J. Knopp, CEO and Co-founder. "Handheld revenue grew 19% year to date and we expect that to further accelerate in the fourth quarter. This underscores the value our handheld devices bring to our customers, aiding them in enhancing public safety during t
908 Devices Inc. (NASDAQ:MASS), a pioneer of purpose-built handheld and desktop devices for chemical analysis, has appointed Michele M. Leonhart, the former Administrator of the United States Drug Enforcement Administration (DEA), to serve on its Board of Directors effective immediately. Ms. Leonhart brings a deep understanding of our customers in law enforcement and adjacent markets. Her 34-year career in the DEA encompassed various positions with increasing levels of responsibility, including Special Agent in Charge of the Los Angeles Field Division from 1998 to 2003, Deputy Administrator (nominated by President Bush) from 2003 to 2007, Acting Administrator from 2007 to 2010, and Admini
908 Devices (NASDAQ:MASS), a pioneer of purpose-built handheld and desktop mass spectrometry devices for chemical and biomolecular analysis, has appointed Tony J. Hunt, President and CEO, Repligen Corporation (NASDAQ:RGEN), to serve on its Board of Directors effective immediately. Mr. Hunt brings a deep understanding of the bioprocessing market, with more than 20 years of life sciences management experience. He joined Repligen in 2014 as Chief Operating Officer and was promoted to his current role a year later. Mr. Hunt previously was President of Bioproduction at Life Technologies, which was acquired by Thermo Fisher Scientific in 2014. From 2000 to 2008, he was with Applied Biosystems as
Company appoints six new members to SAB to maximize the company's impact in the proteomics domain 908 Devices (NASDAQ:MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced the forthcoming appointment of six new individuals to its Scientific Advisory Board (SAB), including Prof. Ileana Cristea, Prof. Jennifer E. Van Eyk, Prof. Anne-Claude Gingras, Prof. Jesper Olsen, Prof. Renã Robinson, and Prof. John Yates. The new SAB members join the board's co-chairs, Christopher D. Brown, CTO 908 Devices; and J. Michael Ramsey, Scientific Founder of 908 Devices and Professor at UNC Chapel Hill, and existing members Prof. Jarrod
Company Appoints Six New Members to its Scientific Advisory Board 908 Devices (NASDAQ:MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced the forthcoming appointment of six new individuals to its Scientific Advisory Board (SAB), including Professor Michael Betenbaugh, Dr. Tim Charlebois, Dr. Elena Chernokalskaya, Dr. John Erickson, Professor Krishnedndu Roy and Dr. Gene Schaefer. The new SAB members join the board's co-chairs Christopher D. Brown, CTO of 908 Devices, and J. Michael Ramsey, Scientific Founder of 908 Devices and Professor at UNC Chapel Hill. "We are honored to be welcoming Michael, Tim, Elena, John
Experienced HR executive with global tech background joins executive leadership team 908 Devices (NASDAQ:MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced that Michele Fournier has joined the company as Chief People Officer. Bringing more than thirty years of global human resources experience in corporate and consulting roles, Michele will lead human resource strategies, processes, and systems to optimize business and talent outcomes for 908 Devices. In this new role, Michele will build a strong talent acquisition pipeline, promote inclusion and diversity in the workplace, and help shape and define employee car
BOSTON--(BUSINESS WIRE)--908 Devices Inc. (NASDAQ: MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced it has appointed Jeff George and Fenel Eloi to serve on its Board of Directors, effective immediately. Mr. George brings more than two decades of global healthcare and corporate leadership experience across North America, Europe, and emerging markets. He served as the global division head and CEO of two $10 billion divisions of Novartis, Sandoz and Alcon, between 2008 and 2016, where in parallel he served on the Novartis Group executive committee. He also serves on the board of directors of Amneal Pharm
BOSTON--(BUSINESS WIRE)--908 Devices (NASDAQ:MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced the appointment of industry veteran Steve Davenport as Vice President of Commercial Sales. Contributing to the record number of life sciences companies that went public in 2020, 908 Devices is now executing on its vision by bolstering the leadership team as it builds out channels to reach and serve bioprocess customers. “The bioprocessing market is an exciting growth area for us as our products help biologists and researchers accelerate therapeutic development,” said Dr. Kevin J. Knopp, CEO of 908 Devices. “H